Biotechnology (190) | Change of Control Agreements (190)

Browse by Company

4D Molecular Therapeutics Inc (4)
AbbVie Inc. (1)
Adverum Biotechnologies, Inc. (8)
Aldeyra Therapeutics, Inc. (1)
Alector, Inc. (1)
Aligos Therapeutics, Inc. (1)
ALNYLAM PHARMACEUTICALS, INC. (1)
ALX ONCOLOGY HOLDINGS INC (1)
AMARIN CORP PLC (1)
Applied Molecular Transport Inc. (1)
Arcellx, Inc. (2)
Arcutis Biotherapeutics, Inc. (11)
ARDELYX, INC. (2)
AVEO PHARMACEUTICALS INC (5)
BioAtla, Inc. (1)
Biomea Fusion, Inc. (1)
Bolt Biotherapeutics, Inc. (1)
CareDx, Inc. (1)
CASI Pharmaceuticals, Inc. (1)
Constellation Alpha Capital Corp. (2)
Cortexyme, Inc. (11)
Corvus Pharmaceuticals, Inc. (1)
CytomX Therapeutics, Inc. (8)
Day One Biopharmaceuticals Holding Co LLC (1)
Decibel Therapeutics, Inc. (3)
Denali Therapeutics Inc. (1)
Dynamics Special Purpose Corp. (3)
Dyne Therapeutics, Inc. (2)
Edge Therapeutics, Inc. (1)
Epizyme, Inc. (2)
Erasca, Inc. (1)
FIBROGEN INC (1)
Global Blood Therapeutics, Inc. (5)
IDERA PHARMACEUTICALS, INC. (2)
IGM Biosciences, Inc. (1)
Imago BioSciences, Inc. (1)
IMMUNOGEN INC (3)
Invitae Corp (3)
Janux Therapeutics, Inc. (1)
Kiniksa Pharmaceuticals, Ltd. (1)
Kinnate Biopharma Inc. (5)
Kronos Bio, Inc. (2)
MeiraGTx Holdings plc (1)
MiNK Therapeutics, Inc. (1)
Morphic Holding, Inc. (5)
Myriad Genetics, Inc. (1)
NOVAVAX INC (1)
Nurix Therapeutics, Inc. (2)
OncoCyte Corp (4)
ONCOSEC MEDICAL Inc (1)
Organogenesis Holdings Inc. (3)
ORGANOVO HOLDINGS, INC. (1)
Oric Pharmaceuticals, Inc. (1)
Oyster Point Pharma, Inc. (1)
PMV Pharmaceuticals, Inc. (7)
Poseida Therapeutics, Inc. (1)
Principia Biopharma Inc. (1)
RECURSION PHARMACEUTICALS, INC. (2)
RenovoRx, Inc. (3)
ROCKET PHARMACEUTICALS, INC. (1)
Sage Therapeutics, Inc. (1)
Sarepta Therapeutics, Inc. (1)
SELLAS Life Sciences Group, Inc. (1)
Sigilon Therapeutics, Inc. (1)
Silverback Therapeutics, Inc. (1)
Sorrento Therapeutics, Inc. (1)
SPRUCE BIOSCIENCES, INC. (2)
Stoke Therapeutics, Inc. (4)
SUTRO BIOPHARMA, INC. (2)
T2 Biosystems, Inc. (4)
Talaris Therapeutics, Inc. (1)
Taysha Gene Therapies, Inc. (1)
Tenaya Therapeutics, Inc. (1)
Tocagen Inc (1)
Vaxcyte, Inc. (1)
VERACYTE, INC. (12)
Vertex Pharmaceuticals Inc (4)
Vir Biotechnology, Inc. (1)
VITAL THERAPIES INC (1)
Vor Biopharma Inc. (1)
ZAFGEN, INC. (5)

Recent Contracts

Amended & Restated Change in Control and Executive Severance Plan Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (OncoCyte Corp, Filed With SEC on December 5, 2022)
Form of Change in Control and Severance Agreement (Tocagen Inc, Filed With SEC on November 14, 2022)
Severance and Change in Control Agreement between the Company and Philip Lee (Dynamics Special Purpose Corp., Filed With SEC on November 10, 2022)
Severance and Change in Control Agreement between the Company and Deborah Knobelman (Dynamics Special Purpose Corp., Filed With SEC on November 10, 2022)
Severance and Change in Control Agreement between the Company and Tim Lu (Dynamics Special Purpose Corp., Filed With SEC on November 10, 2022)
Change of Control and Severance Agreement, dated July 18, 2022 by and between Invitae Corporation and Kenneth D. Knight (Invitae Corp, Filed With SEC on November 8, 2022)
Amended and Restated Executive Severance and Change in Control Benefits Plan (Dyne Therapeutics, Inc., Filed With SEC on November 3, 2022)
Form of Agreement Regarding Change in Control by and between AbbVie Inc. and its named executive officers (AbbVie Inc., Filed With SEC on October 14, 2022)
BioAtla, Inc. Management Change of Control Severance Plan (BioAtla, Inc., Filed With SEC on September 21, 2022)
Change in Control and Severance Agreement by and between RenovoRx, Inc. and Angela Gill Nelms, dated August 17, 2022 (RenovoRx, Inc., Filed With SEC on September 19, 2022)